Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic‑based approach

Iwasaki,Hiroyuki; Toda,Soji; Murayama,Daisuke; Kato,Shin; Matsui,Ai

doi:10.3892/mco.2020.2194

Surgical indications and clinical management of benign and malignant follicular thyroid tumors: An algorithmic‑based approach

Authors:
- Hiroyuki Iwasaki
- Soji Toda
- Daisuke Murayama
- Shin Kato
- Ai Matsui
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Asahi‑ku, Yokohama, Kanagawa 241‑8515, Japan
Published online on: December 17, 2020 https://doi.org/10.3892/mco.2020.2194
Article Number: 32
Copyright: © Iwasaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study retrospectively reviewed the treatment courses and results of patients with follicular thyroid tumors, including carcinomas. In the 5 year study period from April 2015 to March 2020, 797 patients with differentiated thyroid carcinoma and 128 patients with follicular tumors (FTs) received surgery or treatment for distant metastases and recurrence at the Kanagawa Cancer Center (Japan). Of these patients, 73 that were diagnosed with follicular thyroid carcinoma (FTC) were included in the present study. An algorithm used for the application of treatment strategies was assessed. The aim of the present study was to examine patients with FT or FTC who were treated at the Kanagawa Cancer Center to devise appropriate treatment strategies and to evaluate the various treatment outcomes of FTC. Pre‑diagnostic serum thyroglobulin and thyroid stimulating hormone levels, follow‑up and overall survival (OS) were investigated in the present study. The results revealed that OS was significantly increased in patients with minimally invasive follicular thyroid cancer (MIFTC) compared with widely invasive follicular thyroid cancer (WIFTC) (log‑rank test, P=0.017). Additionally, OS was significantly higher in patients without distant metastasis at the first consultation compared with those initially diagnosed with distant metastasis (log‑rank test, P=0.023). Although all patients without distant metastasis at the first consultation and those with MIFTC are alive, the 10‑year survival rates were 75.3% for patients with WIFTC and 75.6% for those with distant metastasis at the first consultation. The results of the present study suggested that the prognosis of WIFTC was the worst among patients with FTC and distant metastasis, and that total thyroidectomy surgery and radioactive iodine treatment are essential. Additionally, if the disease progresses, prompt inclusion of tyrosine kinase inhibitor therapy is necessary.

View Figures

View References

1	Deandrea M, Motta M, Divito L, Mormile A, Gallone G, Grassi A, Pellerito R, Nasi P, Torchio B, Garberoglio R and Fonzo D: Thyroid cytology and risk of thyroid cancer: Differences among indeterminate specimens. Endocr Pract. 10:330–334. 2004.PubMed/NCBI View Article : Google Scholar
2	Renshaw AA and Gould EW: Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine-needle aspiration. Cancer Cytopathol. 124:729–736. 2016.PubMed/NCBI View Article : Google Scholar
3	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
4	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016.PubMed/NCBI View Article : Google Scholar
5	Kim M, Han M, Lee JH, Song DE, Kim K, Baek JH, Shong YK and Kim WG: Tumour growth rate of follicular thyroid carcinoma is not different from that of follicular adenoma. Clin Endocrinol (Oxf). 88:936–942. 2018.PubMed/NCBI View Article : Google Scholar
6	Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT, et al: Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 96:3390–3397. 2011.PubMed/NCBI View Article : Google Scholar
7	Correction to Diagnostic performance of ultrasound-based risk-stratification systems for thyroid nodules: Comparison of the 2015 American thyroid association guidelines with the 2016 Korean thyroid association/korean society of thyroid radiology and 2017 American college of radiology guidelines Ha EJ, Na DG, Moon W-J, Lee YH, and Choi N Thyroid 2018; 28: 1532-1537. DOI: 10.1089/thy.2018.0094. Thyroid 29: 159, 2019.
8	Goffredo P, Cheung K, Roman SA and Sosa JA: Can minimally invasive follicular thyroid cancer be approached as a benign lesion?: A population-level analysis of survival among 1,200 patients. Ann Surg Oncol. 20:767–772. 2013.PubMed/NCBI View Article : Google Scholar
9	Lin JD, Chao TC, Chen ST, Huang YY, Liou MJ and Hsueh C: Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. Surg Oncol. 16:107–113. 2007.PubMed/NCBI View Article : Google Scholar
10	Grani G, Lamartina L, Durante C, Filetti S and Cooper DS: Follicular thyroid cancer and Hurthle cell carcinoma: Challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 6:500–514. 2018.PubMed/NCBI View Article : Google Scholar
11	Stenson G, Nilsson IL, Mu N, Larsson C, Lundgren CI, Juhlin CC, Höög A and Zedenius J: Minimally invasive follicular thyroid carcinomas: Prognostic factors. Endocrine. 53:505–511. 2016.PubMed/NCBI View Article : Google Scholar
12	Lee YM, Song DE, Kim TY, Sung TY, Yoon JH, Chung KW and Hong SJ: Risk factors for distant metastasis in patients with minimally invasive follicular thyroid carcinoma. PLoS One. 11(e0155489)2016.PubMed/NCBI View Article : Google Scholar
13	Iwasaki H, Matsumoto A, Ito K, Kure Y, Suzuki A, Sugino K, Ozaki O and Noh J: Prediction of distant metastasis in follicular adenocarcinoma of the thyroid. World J Surg. 14:425–430. 1990.PubMed/NCBI View Article : Google Scholar
14	Gulcelik MA, Gulcelik NE, Kuru B, Camlibel M and Alagol H: Prognostic factors determining survival in differentiated thyroid cancer. J Surg Oncol. 96:598–604. 2007.PubMed/NCBI View Article : Google Scholar
15	Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G and Niederle B: Prognostic factors of papillary and follicular thyroid cancer: Differences in an iodine-replete endemic goiter region. Endocr Relat Cancer. 11:131–139. 2004.PubMed/NCBI View Article : Google Scholar
16	Verburg FA, Mäder U, Luster M and Reiners C: Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 71:291–297. 2009.PubMed/NCBI View Article : Google Scholar
17	Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et al: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 99:E754–E765. 2014.PubMed/NCBI View Article : Google Scholar
18	Jang EK, Song DE, Sim SY, Kwon H, Choi YM, Jeon MJ, Han JM, Kim WG, Kim TY, Shong YK and Kim WB: NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. Thyroid. 24:1275–1281. 2014.PubMed/NCBI View Article : Google Scholar
19	de Melo TG, Zantut-Wittmann DE, Ficher E and da Assumpcao LV: Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up. J Endocrinol Invest. 37:1195–1200. 2014.PubMed/NCBI View Article : Google Scholar
20	Lee YM, Lee YH, Song DE, Kim WB, Sung TY, Yoon JH, Chung KW and Hong SJ: Prognostic impact of further treatments on distant metastasis in patients with minimally invasive follicular thyroid carcinoma: Verification using inverse probability of treatment weighting. World J Surg. 41(1144)2017.PubMed/NCBI View Article : Google Scholar
21	Biondi B and Cooper DS: Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 20:135–146. 2010.PubMed/NCBI View Article : Google Scholar
22	Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E, Mortara L, Seriolo B and Giusti M: Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol Pol. 67:350–358. 2016.PubMed/NCBI View Article : Google Scholar
23	Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Hatori S, Toda S and Masudo K: Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors. Oncol Lett. 17:5292–5300. 2019.PubMed/NCBI View Article : Google Scholar